AQS Bio becomes the first consulting services company to orchestrate one of the first licensing agreements between a Japanese biopharma and a top 15 Chinese biopharma, for a novel clinical stage obesity asset, for the East Asia territory.
AQS Bio becomes the first consulting services company to orchestrate one of the first licensing agreements between a Japanese biopharma and a top 15 Chinese biopharma, for a novel clinical stage obesity asset, for the East Asia territory.